PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Pivovarova, O.* ; von Loeffelholz, C.* ; Ilkavets, I.* ; Sticht, C.* ; Zhuk, S.* ; Murahovschi, V.* ; Lukowski, S.* ; Döcke, S.* ; Kriebel, J. ; de Las Heras Gala, T. ; Malashicheva, A.* ; Kostareva, A.* ; Lock, J.F.* ; Stockmann, M.* ; Grallert, H. ; Gretz, N.* ; Dooley, S.* ; Pfeiffer, A.F.* ; Rudovich, N.N.*

Modulation of insulin degrading enzyme activity and liver cell proliferation.

Cell Cycle 14, 2293-2300 (2015)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Diabetes mellitus type 2 (T2DM), insulin therapy, and hyperinsulinemia are independent risk factors of liver cancer. Recently, the use of a novel inhibitor of insulin degrading enzyme (IDE) was proposed as a new therapeutic strategy in T2DM. However, IDE inhibition might stimulate liver cell proliferation via increased intracellular insulin concentration. The aim of this study was to characterize effects of inhibition of IDE activity in HepG2 hepatoma cells and to analyze liver specific expression of IDE in subjects with T2DM. HepG2 cells were treated with 10 nM insulin for 24 h with or without inhibition of IDE activity using IDE RNAi, and cell transcriptome and proliferation rate were analyzed. Human liver samples (n=22) were used for the gene expression profiling by microarrays. In HepG2 cells, IDE knockdown changed expression of genes involved in cell cycle and apoptosis pathways. Proliferation rate was lower in IDE knockdown cells than in controls. Microarray analysis revealed the decrease of hepatic IDE expression in subjects with T2DM accompanied by the downregulation of the p53-dependent genes FAS and CCNG2, but not by the upregulation of proliferation markers MKI67, MCM2 and PCNA. Similar results were found in the liver microarray dataset from GEO Profiles database. In conclusion, IDE expression is decreased in liver of subjects with T2DM which is accompanied by the dysregulation of p53 pathway. Prolonged use of IDE inhibitors for T2DM treatment should be carefully tested in animal studies regarding its potential effect on hepatic tumorigenesis.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.565
0.937
26
29
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Ccng2 Cyclin G2 Gene ; Cdkn1a/p21 Cyclin-dependent Kinase Inhibitor 1a (p21, Cip1) Gene ; Cdkn1b/p27 Cyclin-dependent Kinase Inhibitor 1b (p27, Kip1) Gene ; Fas Fas Cell Surface Death Receptor Gene ; Fbs Fetal Bovine Serum ; Hepatocellular Carcinoma ; Ide Insulin-degrading Enzyme ; Insulin-degrading Enzyme ; Mcm2 Minichromosome Maintenance Complex Component 2 Gene ; Mki67 Marker Of Proliferation Ki-67 Gene ; Nafld Non-alcoholic Fatty Liver Disease ; Nas Non-alcoholic Fatty Liver Disease Score ; Non-alcoholi; Fatty Liver; Hepatocellular-carcinoma; Disease; Degradation; Expression; Protein; Cancer
Sprache englisch
Veröffentlichungsjahr 2015
HGF-Berichtsjahr 2015
ISSN (print) / ISBN 1538-4101
e-ISSN 1551-4005
Zeitschrift Cell Cycle
Quellenangaben Band: 14, Heft: 14, Seiten: 2293-2300 Artikelnummer: , Supplement: ,
Verlag Landes Bioscience
Verlagsort Philadelphia
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Epidemiology (EPI)
POF Topic(s) 30202 - Environmental Health
90000 - German Center for Diabetes Research
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-504091-002
G-504000-002
G-501900-402
PubMed ID 25945652
DOI 10.1080/15384101.2015.1046647
WOS ID WOS:000358126400020
Scopus ID 84943775291
Erfassungsdatum 2015-06-03
[➜Korrektur melden]